Larry Marnett and colleagues have developed what may become the first agent for targeted PET imaging of cancer tissues, such as ovarian cancer, that express high levels of the COX-1 enzyme.

Understanding how a steroid-metabolizing enzyme binds to its substrates may aid in designing drugs to treat sexual dysfunction as well as prostate cancer.

Vanderbilt investigators have characterized how a new first-in-class antibacterial drug works, which will guide the development of additional compounds that overcome antibacterial resistance.

Stephen Fesik and colleagues are advancing cancer drug discovery with the characterization of small molecules that modulate RAS, an important target for anti-cancer therapies.

A precise understanding of how the enzyme topoisomerase II cuts DNA could lead to better anti-cancer therapies.

The discovery that kidney cells with mutations in a certain gene are sensitive to therapies called PI3K inhibitors opens new opportunities for applying precision medicine to cancer treatment.

Biochemistry investigators at Vanderbilt have discovered a new DNA repair mechanism that prevents gene mutations during DNA replication.